Clinical trialObsCompleted
Multimodal Deep Learning Model Predicts Pancreatic Cancer Prognosis
Prediction of Pancreatic Cancer Prognosis Using a Multimodal Deep Learning Model Based on Intratumoral Immune Microenvironment
- Outcome
- Finished, no results posted
- Phase
- Obs
- Status
- Completed
- Study type
- Observational
- Start
- 5 July 2024
- Expected end
- 3 January 2026
- Enrollment
- 247 participants
- Sites
- 1
- Primary outcomes
- Performance of deep learning model
- Sponsor
- Other
- Results posted
- No
- Last update
- 7 January 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study describes the development and validation of a deep learning prediction model, which extracts deep learning features from preoperative enhanced CT scans and analyzes postoperative pathological specimens of pancreatic cancer patients. The aim is to predict patient prognosis and response to chemotherapy treatment.
Detailed description public domain (ClinicalTrials.gov)
This study retrospectively collected enhanced CT scan data, pathological paraffin blocks, and clinical data from pancreatic cancer patients who underwent surgery at multiple centers between March 2013 and May 2024. The pathological paraffin blocks were stained using immunohistochemistry for prognostic immune microenvironment markers, and patients were classified based on these results. Subsequently, deep learning features were extracted from enhanced CT scans, and a multimodal prediction model was constructed using imaging features and clinical information. The model's performance was evaluated using metrics including area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, and specificity.